August 2014

In July, 2014, a team of Norwegian researchers led by K.O. Nakken published an article in Tidsskr Nor Laegeforen titled “Antiepileptic drugs and congenital malformations”, evaluating the consequences of prenatal exposure to epilepsy drugs containing sodium valproate, such as Depacon, Depakene, and Depakote (Abbott Laboratories, Inc.).  To-date, dozens of

From Stockholm, Sweden, a 2008 piece titled “Teratogenic effects of antiepileptic drugs.” and appearing in the medical journal, Seizure, by T. Tomson et al. yet again demonstrates the postnatal risks of prenatal exposure to epilepsy drugs containing sodium valproate such as Depakote, Depakene, and Depacon (Abbott Laboratories, Inc.).

Here, it is stated

Titled “Malformation in infants of mothers with epilepsy receiving antiepileptic drugs.”, a piece of Japanese medical research by S. Kaneko et al. published in April, 1992 helps show just how long it has been known that prenatal exposure to epilepsy drugs containing valproate is linked to birth defects.  Depacon, Depakote, and Depakene are